"Metastatic head" trang 1 - tải miễn phí từ tailieuXANH
Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma

Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma
15    123    0
Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial

Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial
10    58    0
Rationale and design of LUX-Head & Neck 1: A randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy

Rationale and design of LUX-Head & Neck 1: A randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy
9    61    0
The head and neck in surgical pathology (Volume 2 - Second edition): Part 2

The head and neck in surgical pathology (Volume 2 - Second edition): Part 2
422    65    0
Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: Realworld data in Korea

Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: Realworld data in Korea
9    52    0
Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: A randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimen

Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: A randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimen
10    69    0
An effective and well-tolerated strategy in recurrent and/or metastatic head and neck cancer: Successive lines of active chemotherapeutic agents

An effective and well-tolerated strategy in recurrent and/or metastatic head and neck cancer: Successive lines of active chemotherapeutic agents
8    138    0
Treatment response lowers tumor symptom burden in recurrent and/or metastatic head and neck cancer

Treatment response lowers tumor symptom burden in recurrent and/or metastatic head and neck cancer
11    88    0
Real-world study of the impact of recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) on quality of life and productivity in Europe

Real-world study of the impact of recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) on quality of life and productivity in Europe
12    245    1
Rituximab in combination with gemcitabine plus cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma: A phase I trial

Rituximab in combination with gemcitabine plus cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma: A phase I trial
10    16    1
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.